All In Biotech

Drug Trial Radar · NCT07914556

Phase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers

A Phase 1, Safety, Pharmacokinetic, Immunogenicity, and Preliminary Efficacy Study of 6MW5311 in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients, in Chronic Myelomonocytic Leukemia (CMML) Patients and Multiple Myeloma (MM) Patients

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

122

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess safety and tolerability at increasing dose levels of 6MW5311 in successive cohorts of participants with MM, AML and CMML in order to estimate the maximum tolerated dose (MTD) and select the recommended Phase 2 dose (RP2D) or the recommended expansion dose (RED).

Conditions

  • AML
  • Multiple Myeloma
  • CMML

Interventions

  • 6MW5311Biological

    A bispecific T cell engager (TCE) antibody: bivalent binding to LILRB4 on tumor cells and monovalent binding to CD3 on T cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose-limiting toxicities (DLTs)Time frame: From the first dose of Cycle 1 through Day 28 of Cycle 1 (each cycle is 28 days)
  2. Number of participants with treatment-emergent adverse events (TEAEs)Time frame: From first dose through 28 days after the last dose, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Jiao Tong University School of Medicine, Ruijin Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.